

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 February 2010 (04.02.2010)

(10) International Publication Number
WO 2010/014723 A1

PCT

(51) International Patent Classification:
G01N 33/564 (2006.01)

(21) International Application Number:
PCT/US2009/052121

(22) International Filing Date:
29 July 2009 (29.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/084,504 29 July 2008 (29.07.2008) US

(71) Applicant (for all designated States except US): **THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 201 W. 7th St., Austin, TX 78701 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHRISTADOSS, Premkumar** [US/US]; 3008 Seapines Place, League City, TX 77573 (US). **ALLMAN, Windy** [US/US]; 1127 Sealy Ave., Galveston, TX 77550 (US).

(74) Agent: **LANDRUM, Charles, P.**; Fulbright & Jaworski L.L.P., 600 Congress Ave., Suite 2400, Austin, TX 78701 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS AND COMPOSITION RELATED TO ACETYLCHOLINE RECEPTOR CONJUGATES

(57) Abstract: Disclosed are methods, compositions, and diagnostic kits for detecting acetylcholine receptor (AChR) autoreactive immune cells in a subject. The methods comprise detecting the binding of AChR-conjugate to peripheral blood AChR-specific B cells for diagnosing autoimmune disorders, including Myasthenia gravis (MG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). More specifically, the detection is achieved by using flow cytometric assay with Alexa-conjugated AChR.



WO 2010/014723 A1

DESCRIPTION**METHODS AND COMPOSITION RELATED TO ACETYLCHOLINE RECEPTOR CONJUGATES****BACKGROUND OF THE INVENTION**

[0001] This application claims priority to U.S. Provisional Patent Application serial number 61/084,504 filed July 29, 2008, which is incorporated herein by reference in its entirety.

I. FIELD OF THE INVENTION

[0002] Embodiments of this invention are directed generally to immunology and medicine. In certain embodiments the invention is directed to detection of autoreactive immune cell (B cell) that recognize the acetylcholine receptor.

II. BACKGROUND

[0003] Myasthenia gravis (MG) is a human autoimmune disorder characterized by muscle weakness and fatigability. In this disease, antibodies against the acetylcholine receptor (AChR) bind to the receptor and destroy the receptor and thus interfere with the transmission of signals from nerve to muscle at the neuromuscular junction (Patrick and Lindstrom, 1973).

[0004] The acetylcholine receptor molecule is a transmembrane glycoprotein consisting of five subunits, two α , one β , one δ , with either an ϵ or γ subunit, organized in a barrel-staves-like structure around a central cation channel (Karlin, 1980; Changeux *et al.*, 1984). Noda *et al.* (1983) described the cloning and sequence analysis of human genomic DNA encoding the α -subunit precursor of muscle acetylcholine receptor, and Schoepfer *et al.* (1988) reported the cloning of the α -subunit cDNA from the human cell line TE671. Human muscle AChR α -subunit exists in two forms, one of which has 25 additional amino acid residues, inserted between positions 58 and 59, that are coded by the 75 bp exon p3A (Beeson *et al.*, 1990). The α -subunit of AChR contains both the site for acetylcholine binding and is the immunodominant region for anti-AChR immune responses. However, antibodies have been detected against all subunits of AChR.

[0005] The autoimmune response in myasthenia gravis is directed mainly towards the extracellular domain of the AChR α -subunit (amino acids 1-210), and within it, primarily

towards the main immunogenic region (MIR) encompassing amino acids 61-76 (Tzartos and Lindstrom, 1980; Tzartos *et al.*, 1987; Loutrari *et al.*, 1992). Many antibodies to the MIR bind only to the native conformation of the α subunits because they bind to sequences that are adjacent only in the native structure.

[0006] MG is currently treated by acetylcholinesterase inhibitors and by non-specific immunosuppressive drugs that have deleterious side effects. It would be preferable to treat MG with a method that involves antigen-specific immunotherapy but leaves the overall immune response intact. One such strategy of specific therapy could involve the administration of derivatives of AChR that do not induce myasthenia but are capable of affecting the immunopathogenic antibodies. However, since the anti-AChR antibody repertoire in myasthenia gravis has been shown to be polyclonal and heterogeneous (Drachman, 1994), the regulation of the disease requires modulation of many antibody specificities.

[0007] Previous studies were directed towards modulating the anti-AChR response and EAMG by either derivatives of Torpedo AChR, *e.g.*, the reduced and carboxymethylated derivative, RCM-AChR (Bartfeld and Fuchs, 1978), synthetic peptides corresponding to Torpedo acetylcholine receptor (Shenoy *et al.*, 1993), specific regions of AChR (Shenoy *et al.*, 1993; Souroujon *et al.*, 1992; Souroujon *et al.*, 1993), or mimotopes selected from an epitope library (Balass *et al.*, 1993). The Torpedo RCM-AChR did not induce EAMG in rabbits and was effective in suppressing the disease. However, RCM-AChR did induce EAMG in rats. The experiments carried out with the synthetic peptides and mimotopes were only partially successful in neutralizing MG autoimmune response, probably due to the incorrect folding of the short peptides that were recognized by only a portion of the anti-AChR antibodies and ineffective tolerance to acetylcholine receptor specific B cells.

[0008] MG is currently diagnosed by testing for antibodies against AChR by radioimmunoassay wherein the antigen is crude AChR extracted from human muscle or TE671 cells. This test presents some drawbacks, namely the antigen is not readily available and, in addition, the antibody titers detected are not well correlated with disease severity.

[0009] Thus, additional methods and compositions that are both reliable and convenient diagnostic test is needed.

SUMMARY OF THE INVENTION

[0010] Myasthenia Gravis is a chronic autoimmune condition characterized by fluctuating voluntary muscle weakness. Antibodies to acetylcholine receptors (AChR) destroy AChR in the neuromuscular junctions leading to MG. Symptoms of MG include fatigue, muscle weakness, double vision, drooping eyelids, and difficulty chewing or swallowing and in severe disease paralysis and respiratory distress. Currently, diagnosis of MG involves a combination of clinical history, nerve stimulation tests, and blood test for serum antibodies against AChR. Although serum antibodies to AChR are diagnostic for MG, the antibody titer does not correlate with disease severity and around 15% of patients with MG do not have serum antibodies to AChR. Therefore, a better marker for disease state is required to evaluate the clinical effectiveness of specific drugs in MG. Also the current test for anti-AChR antibodies, either radioimmunoassay or ELISA takes two days and has to be performed in special Medical centers like Mayo Clinic. The inventors have developed a simple novel reagent and/or kit comprising AChR conjugates, such as an Alexa-AChR conjugate, for flowcytometry of patient blood. The methods described herein typically use no radioactivity, and can screen MG patient blood samples in little over an hour for increased frequency of AChR+ B cells. This test could be performed in any hospitals or institutions having a FACS machine or access to such a facility or service. Since anti-AChR antibodies are secreted versions of the membrane bound B cell receptor (BCR) in MG patients, the inventors use AChR conjugates, *e.g.*, Alexa-fluor AChR conjugates, to identify pathogenic AChR-specific B cells in blood of MG patients.

[0011] The present invention provides methods for monitoring MG in a subject comprising the steps of determining the presence and/or number of AChR reactive B-cells in a sample from the subject, determining the levels in a control sample, and assessing MG status in the subject relative to the control. Furthermore, this invention also describes how one can isolate and assess the function and biology of specific autoreactive cells that bind AChR.

[0012] Certain aspects of the invention includes methods of evaluating a patient for or with Myasthenia Gravis comprising the steps of: (i) contacting a sample comprising B cells with an acetylcholine receptor (AChR) conjugate; (ii) determining a level of AChR binding B cells in a sample; and (iii) comparing the level of AChR reactive B-cells with a reference or standard. In certain aspects the sample is a blood sample. In a further aspect the AChR conjugate comprises a fluorophore, such as, but not limited to Alexa fluorophore (*e.g.*, Alexa-

488 or Alexa-647). In other aspects determining a level of AChR binding B cells is by flow cytometry.

[0013] In other aspects the method can further comprise contacting the sample with B cell marker binding agent, such as but not limited to an antibody that binds a cell surface molecule including, but not limited to IgG, CD19, CD21, CD45R, CD20, CD22, CD23, and/or CD81.

[0014] In still further aspects, the methods can further comprise administering a treatment for myasthenia gravis.

[0015] In yet a further aspect includes a reagent and/or device for evaluating a patient of myasthenia gravis comprising an AChR conjugate.

[0016] In certain aspects the invention is directed to an acetylcholine receptor conjugate comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 50, 100 or more consecutive amino acids, including all values and ranges there between of an AChR polypeptide coupled to a detectable moiety.

[0017] Also contemplated are kits for detecting acetylcholine receptor reactive B cells comprising an acetylcholine receptor conjugate.

[0018] Certain aspects are also directed to methods of evaluating a patient for or with an autoimmune condition comprising the steps of: (i) contacting a sample comprising B cells with a protein or peptide conjugate that specifically binds a B cell associated with the autoimmune condition; (ii) determining a level of conjugate binding B cells in a sample; and (iii) comparing the level of conjugate reactive B-cells with a reference or standard. In certain aspects the autoimmune condition is MG, SLE or rheumatoid arthritis.

[0019] As used herein, the term "B cell" refers to a cell produced in the bone marrow expressing membrane-bound antibody specific for an antigen, in this case AChR. Following interaction with the antigen it differentiates into a plasma cell which secretes antibodies specific for the antigen or into a memory B cell. "B cell" and "B lymphocyte" is used interchangeably.

[0020] As used herein, the term "antigen-specific B cell" refers to a B cell which expresses antibodies that are able to distinguish between the antigen of interest (*e.g.*, AChR) and other

antigens and which specifically bind to that antigen of interest with high or low affinity but which do not bind to other antigens.

[0021] A "positive B cell" means any B cell which is labeled with any one of the labeling compounds of the invention and which is selected or sorted or otherwise separated from a mixture of cells by a device capable of detecting said labeling compound. For example, a B cell which is positive for a labeling compound of the invention is a B cell which is labeled with a labeling compound and which is selected by the device capable of detecting the labeling compound.

[0022] As used herein, the term "B cell marker" refers to surface molecules on the B cells which are specific for particular B cells. B cell markers suitable for use in the present invention include, but are not limited to surface IgG, kappa and lambda chains, Ig-alpha (CD79alpha), Ig-beta (CD79beta), CD19, B220 (CD45R), CD20, CD21, CD22, CD23, CD27, or any other CD antigen specific for B cells.

[0023] The term "bind" or "bound" refers to binding or attachment that may be covalent, e.g., by chemically coupling, or non-covalent, e.g., ionic interactions, hydrophobic interactions, hydrogen bonds, *etc.* Covalent bonds can be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like. The term "bound" is broader than and includes terms such as "coupled," "fused," "associated," and "attached."

[0024] As used herein, the term "labeling compound" refers to a compound used to label the AChR polypeptides or one or more B cell markers of the invention either directly or indirectly through, for example, a covalent bond, a tag, antibody, dioxigenin, or biotin. Such labels suitable for use in the present invention are well known in the art and include, but are not limited to fluorescent materials (e.g., PerCP, Allophycocyanin (APC), texas red, rhodamine, Cy3, Cy5, Cy5.5, Cy7, Alexa Fluor Dyes, phycoerythrin (PE), green fluorescent protein (GFP), a tandem dye (e.g., PE-Cy5), fluorescein isothiocyanate (FITC)), magnetic beads, radiolabel (e.g., ¹³¹I-labeled antibody, ⁹⁰Y (a pure beta emitter)-labeled antibody, ²¹¹At-labeled antibody), an enzyme, avidin or biotin, or any other tag or label known in the art useful for labeling AChR polypeptide and/or at least a second B cell marker.

[0025] The composition of the invention can be labeled prior to or after contacting a sample comprising a mixture of cells with an AChR polypeptide. The AChR polypeptide can

be labeled with a labeling compound such as avidin or biotin, dioxigenin, flag tag or any other tag known in the art. A detectable moiety can then be bound to the AChR polypeptide through a covalent bond, a labeled streptavidin, anti-dioxigenin, anti-flag or any other anti-tag. The sample may also be contacted with a second composition comprising an antibody to one or more B cell marker. Detectable moieties include, but are not limited to fluorescent materials, magnetic particles or radiolabels.

[0026] In one embodiment, two or more samples may be taken from a subject. A first sample can be taken from the subject before treatment with a therapeutic agent, which for example, establishes a baseline to compare subsequent sample(s). A second sample can then be taken after treatment with the therapeutic agent to assess the effects of treatment.

[0027] In another embodiment, the test sample is from the subject who has or is suspected of having MG and the control sample is from a subject that does not have MG. In certain aspects, these methods and compositions are useful for determining B cell levels in any subject for whom the knowledge of the B cell levels in the subject would be helpful in treating or managing MG. Therefore, this method can be useful for monitoring or treating subjects having or suspected of having MG or monitoring a subject with MG. Thus, this method is useful for monitoring B cells associated with MG.

[0028] The present invention also provides kits and articles of manufacture for assaying AChR reactive B-cells levels in a subject. A kit may comprise AChR conjugate and one or more detectable moieties as well the reagents needed to express, purify, manipulate, and/or label an AChR polypeptide.

[0029] Other embodiments of this invention also include similar conjugation procedure to conjugate Alexa or other dyes with proteins or peptides that bind to B cells associated with other autoimmune diseases to detect frequency of antigen specific B cells in these diseases. Examples of autoimmune diseases and relevant proteins (autoantigens) involved in the development of these autoimmune diseases are given in Table 1. A conjugate of these autoantigens are contemplated for the assessment of these autoimmune disorders.

Table 1. Other autoimmune diseases and their autoantigen(s).

Autoimmune Diseases	Autoantigens
Systemic lupus erythematosus (SLE)	DNA, RNA, Smith (SM) antigen
Hashimoto's thyroiditis	Thyroglobulin (Tg)
Uveitis	Interphotoreceptor retinoid binding protein (IRBP)
Rheumatoid arthritis (RA)	Type II collagen, rheumatoid factor
Type I diabetes (IDDM)	Islet b cell antigens, glutamic acid decarboxylase (GAD), and insulin
Graves' disease (Thyrotoxicosis)	Thyroid stimulatory hormone receptor (TSHR)
Goodpasture's syndrome	Type IV collagen
Pemphigus vulgaris	Desmoglein 2
Pemphigoid	Epidermal basement membrane protein
Pernicious anemia	Intrinsic factor, gastric parietal cell antigen
Addison's disease	Adrenal gland antigen
Autoimmune haemolytic anemia	Erythrocyte membrane protein
Idiopathic thrombocytopenic purpura	Platelet membrane protein
Multiple sclerosis	Myelin basic protein (MBP). Myelin oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP)
Primary biliary cirrhosis	Pyruvate dehydrogenase
Celiac disease	Gluten (gliadin)
Vasculitis	Neutrophil cytoplasmic antigen
Sjogren's syndrome	Ribonucleoprotein antigens (RO/SSA and La/SSB)

[0030] Other embodiments of the invention are discussed throughout this application. Any embodiment discussed with respect to one aspect of the invention applies to other aspects of the invention as well and vice versa. The embodiments in the Example section are understood to be embodiments of the invention that are applicable to all aspects of the invention.

[0031] The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[0032] It is contemplated that any embodiment discussed herein can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions and kits of the invention can be used to achieve methods of the invention.

[0033] Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0034] The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”

[0035] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0036] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

[0037] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0038] **FIG. 1** A portion of affinity-purified AChR is run on an SDS-PAGE gel to test for high purity prior to labeling.

[0039] **FIG. 2** Mature B cells (CD19+CD21+) from CFA-AChR immunized mice have higher levels of Alexa-488 conjugated AChR+ splenocytes than naïve or CFA immunized mice.

[0040] **FIG. 3** Identifying AChR-specific B cells (CD19+) from lymph node of CFA-AChR immunized mice.

[0041] **FIG. 4** Alexa-488 conjugated AChR+ cells are responsible for *in vitro* proliferative responses to AChR. (A) Double positive B cells (B220+AChR+) from CFA-AChR immunized mice were depleted by flow cytometry and (B) then stimulated *in vitro* with AChR.

[0042] **FIG. 5** The characterization of AChR-binding peripheral blood lymphocytes by flow cytometry. Representative flow cytometry analysis of peripheral blood lymphocytes from naïve, LPS-immunized or CFA+AChR-immunized (EAMG) mice, 75 to 80 days post primary immunization. Cells were first gated on lymphocytes and then analyzed for B220 expression and either AChR binding or OVA binding (A). Then lymphocytes were gated on B220+ cells to characterize IgM (B) or IgG2 (C) expression and either AChR binding or OVA binding. The numbers shown in bi-exponential plots indicate the relative percentage of cells in each quadrant. The experiment was repeated 5 times with similar results.

[0043] **FIG. 6** Inhibition of Alexa fluor-AChR-binding to peripheral blood B cells with unlabeled AChR. Representative flow cytometry staining of peripheral blood lymphocytes with (+) or without (-) blocking by incubating cells with (+) unlabeled AChR prior to staining with Alexa fluor-AChR; anti-B220 and anti-IgM, anti-IgG2, or isotype controls (A). The numbers shown in bi-exponential plots indicate the relative percentage of cells in each quadrant. The mean percentage of B-cell, AChR-binding subsets with (+) or without (-) blocking with unlabeled AChR (B). Each circle represents the frequency of AChR-binding B cells after 3 immunizations with CFA+AChR from individual mice having EAMG (n=5). The bar indicates the mean frequency of AChR-binding B cells. The data shown are from one experiment that was repeated three times. *P<.05, **P<.01, ***P<.001. t-test.

[0044] **FIG. 7** The kinetics on the frequencies of AChR-binding B cells. Shown is the mean percentage of subsets of peripheral blood B cells which are AChR-binding from naïve, LPS-immunized or CFA+AChR-immunized (EAMG) mice. Cells were analyzed as shown in Fig. 1. Each square represents the frequency of the total AChR-binding B cells (top row), AChR-binding IgM+ B cells (middle row) or AChR-binding IgG2+ B cells (bottom row) from individual mice with EAMG after each immunization. Significant differences between populations were determined by ANOVA with Tukey's post hoc test and represented by a * P<0.05, **P<0.01, and ***P<0.001. Results shown are combined from multiple flow cytometry experiments with a total n=5-15 mice per group.

[0045] **FIG. 8** Correlation between AChR-binding peripheral blood B cells and markers of disease severity. Each triangle represents the frequency of AChR-binding IgM + (A&B) or IgG2+ (C&D) after 3 immunizations with CFA+AChR from individual mice with EAMG (clinical grades 1-3) and naïve mice (clinical grade 0) (n=5-7 per group). Clinical evaluation was completed at the time of blood draw (day 80). R is the Spearman coefficient between AChR-binding B-cell frequency and clinical grade (A&C) or grip strength loss represented by the grip strength ratio (B&D).

[0046] **FIG. 9** Plasma concentration of secreted anti-AChR Igs does not correlate with the AChR-specific B-cell frequencies in mice with EAMG. Mean IgM (A) and IgG2 (C) expressing AChR-specific B-cell frequencies are shown by open squares with a broken line with SEM, and values are indicated on the left y-axis. Mean and SEM plasma anti-AChR IgM (A) and IgG2 (C) OD values determined by ELISA are shown by open circles with a solid line, and values are indicated on right axis. Spearman correlation between individual plasma anti-AChR IgM (B) or IgG2 (D) concentrations and the frequency of the AChR-binding B cells after day 42 post immunization. Each circle represents data from an individual mouse after each immunization with CFA and AChR. Black arrows indicate time of boost immunizations. Results shown are from one experiment with a total n=4-10 mice. Experiment was repeated with similar results. r, Spearman correlation coefficient; ns, not significant.

[0047] **FIG. 10** Alexa-AxChR binding CD19+ B cells in patients with MG.

DETAILED DESCRIPTION OF THE INVENTION

[0048] Patients with the neuromuscular disease Myasthenia Gravis (MG) are characterized by pathogenic autoantibodies directed towards AChR (Aharonov *et al.*, 1975). The α -subunit of AChR is the immunodominant antigen, and within it especially the extracellular domain. Experimental autoimmune myasthenia gravis (EAMG) is an antibody-mediated autoimmune disease of the neuromuscular junction in which AChR is the major autoantigen and which serves as a model for MG.

[0049] Human muscle AChR α -subunit exists as two isoforms consisting of 437 and 462 amino acid residues (Beeson *et al.*, 1990). The two isoforms are identical in their amino acid composition except for a sequence of 25 additional amino acid residues inserted after position

58 in the extracellular domain of the longer variant. These additional amino acids are encoded by the 75 bp exon p3A.

[0050] The AChR molecule in its native conformation structure, consisting of five subunits, two α , one β , one δ , with either an ϵ or γ subunits are included in present invention. However, this invention may be extended to fragments of AChR capable of binding and labeling a B-cell reactive with AChR as part of the present invention.

[0051] An "autoimmune disease," such as Myasthenia Gravis, is a disease or disorder arising from and directed against an individual's own tissues or organs, or a resulting condition there from. In many autoimmune disorders a number of clinical and laboratory markers may exist including, but not limited to production of autoantibodies. Without being limited to any one theory regarding autoimmune disease, it is believed that B cells demonstrate a pathogenic effect in human autoimmune diseases through a multitude of mechanistic pathways, including autoantibody production, immune complex formation, dendritic and T-cell activation, cytokine synthesis, and/or direct chemokine release. Each of these pathways may participate to different degrees in the pathology of autoimmune diseases such as MG.

[0052] The term "determining" is intended to include any method for evaluating or measuring the amounts of a substance or cell type in a sample. Examples of comparative controls include, but are not limited to, sera from normal healthy patient samples or reference ranges derived the sampling an analysis of a number of subject known not to have MG.

I. ACETYLCHOLINE RECEPTOR

[0053] An acetylcholine receptor (AChR) is an integral membrane protein that responds to the binding of the neurotransmitter acetylcholine. Human acetylcholine receptor consists of subunits, arising from five genes, CHRNA (*e.g.*, Accession No. EAX11127 (GI:119631532); NP_001034612 (GI:87567783); P02708 (GI:113071)), CHRNB2 (*e.g.*, Accession No. CAI16184 (GI:55960912)), CHRND (*e.g.*, Accession No. NP_000742 (GI:4557461)), CHRNE (*e.g.*, Accession No. AAD24503 (GI:4580859)), and CHRNG (*e.g.*, Accession No. P07510 (GI:126302510)), each of which is incorporated herein by reference as of the filing date of this application.

[0054] Molecular biology has shown that the nicotinic and muscarinic receptors belong to distinct protein superfamilies. The nAChRs are ligand-gated ion channels, and, like other members of the "cys-loop" ligand-gated ion channel superfamily, are composed of five protein subunits symmetrically arranged like staves around a barrel. The subunit composition is highly variable across different tissues. Each subunit contains four regions named M1, M2, M3, and M4, which span the membrane and consist of approximately 20 amino acids. The M2 region, which sits closest to the pore lumen, forms the pore lining. Binding of acetylcholine to the N termini of each of the two alpha subunits results in the 15° rotation of all M2 helices. The cytoplasm side of the nAChR receptor has rings of high negative charge that determine the specific cation specificity of the receptor and remove the hydration shell often formed by ions in aqueous solution.

[0055] AChR is found at the edges of junctional folds at the neuromuscular junction on the postsynaptic side, and is activated by acetylcholine release across the synapse. The diffusion of Na⁺ and K⁺ across the receptor causes depolarization, the end-plate potential, that opens voltage-gated sodium channels, which allows for firing of the action potential and potentially muscular contraction.

A. Conjugates

[0056] The invention provides a conjugate that contains a detectable moiety linked to an AChR polypeptide (*e.g.*, affinity purified AchR). In certain aspects, the AChR polypeptide portion of the conjugate can have, for example, a length of at least, at most, or about 5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400, or 450 consecutive amino acid residues, including all values and ranges there between, of for example SEQ ID NOs 1-3. It is understood that the term "AChR polypeptide portion of the conjugate" means the total number of residues in the AChR conjugate. An AChR polypeptide portion of the present invention may be prepared by purification methods, recombinant methods, and/or synthetic methods, all of which are known to one skilled in the art.

[0057] The AChR polypeptide portion according to the present invention may be prepared by recombinant methods. For example, a DNA nucleotide encoding the polypeptide is constructed by a conventional methods. The construction of the DNA nucleotide may be performed by PCR amplification using a suitable primer. Otherwise, the DNA nucleotide may be constructed by a standard method known to one skilled in the art, for example, by an automatic DNA synthesizer (available from Biosearch or Applied Biosystems). The DNA

nucleotide constructed as described above is inserted into a vector containing at least one expression control sequence (*e.g.*, promoter, enhancer, or the like) that is operatively linked to the DNA nucleotide to control the expression of the DNA nucleotide, thereby providing a recombinant expression vector, which, in turn, is used to transform a host cell. The resultant transformed cell can be cultured in a suitable medium and a condition to perform the expression of the DNA sequence. Then, a substantially pure peptide encoded by the DNA nucleotide is recovered from the culture. Such recovery may be carried out by a method generally known to one skilled in the art (*e.g.*, chromatography). As used herein, the term "substantially pure peptide" means a peptide according to the present invention does not substantially comprise any other proteins derived from a host. References to the genetic engineering method for preparing the peptide according to the present invention include: Maniatis *et al.*, 1982; Sambrook *et al.*, 2nd Ed. (1998) and 3rd Ed. (2000); Gene Expression Technology, 1991; and Hitzeman *et al.*, 1990.

[0058] Typical examples of synthetic methods include, but are not limited to, liquid or solid phase synthesis, fragment condensation, F-MOC or T-BOC chemistry ((Creighton, Proteins; Structures and Molecular Principles, 1983; Chemical Approaches to the Synthesis of Peptides and Proteins, 1997; A Practical Approach, 1989).

[0059] In a particular example AChR can be purified from a protein source such a cell line expressing a recombinant polypeptide or from Torpedo Californica electric organs (Aqautic Research Consultants, CA) according to published methods (Wu *et al.* 1997). AChR conjugates can be made by incubating AChR with detectable moiety containing a reactive moiety such as a succinimidyl ester moiety or other know reactive moiety. AChR polypeptides can be concentrated by, for example, centrifugation with centrifugal filters. AChR polypeptide can then be dialyzed and AChR concentration can be determined. AChR can then be contacted with a detectable moiety and/or a labeling reagent. Labeled AChR can then be further purified and concentration of labeled protein determined.

[0060] A number of peptide labeling methods are well known. (See Haugland, 2003; Brinkley, 1992; Garman, 1997; Means and Feeney, 1990; Glazer *et al.*, 1975; Lundblad and Noyes, 1984; Pfeleiderer, 1985; Wong, 1991; De Leon-Rodriguez *et al.*, 2004; Lewis *et al.*, 2001; Li *et al.*, 2002; Mier *et al.*, 2005).

B. Labeling and labels

[0061] In certain aspects an AChR polypeptide is conjugated to a detectable moiety by at least one covalent bond. In one aspect the covalent bond is a non-peptide bond. Typically AChR polypeptide is conjugated to the detectable moiety by way of chemical cross-linking, *e.g.*, by using a heterobifunctional cross-linker. A hetero-bifunctional crosslinker contains a functional group which can react with preferred first attachment sites, *i.e.* chemical groups of the AChR polypeptide and a further functional group which can react with a preferred second attachment site available for reaction with or the detectable moiety, vice versa with the first attachment site on the detectable moiety and the second attachment site on the AChR polypeptide. In certain aspects the chemical group for attachment can be synthesized in the detectable moiety itself, detectable moiety can have one or more attachment group(s). The first step of the procedure, typically called the derivatization, is the reaction of AChR polypeptide or the detectable moiety with the cross-linker. The product of this reaction is an activated AChR polypeptide or detectable moiety. In a second step, unreacted cross-linker is removed using usual methods such as column filtration, gel filtration, or dialysis.

[0062] Several hetero-bifunctional cross-linkers are known to the art. These include the preferred cross-linkers SMPH (Pierce), Sulfo-MBS, Sulfo-EMCS, Sulfo-GMBS, Sulfo-SIAB, Sulfo-SMPB, Sulfo-SMCC, SVSB, SIA and other cross-linkers available for example from the Pierce Chemical Company (Rockford, Ill., USA). The above mentioned cross-linkers all lead to formation of a thioether linkage. Other cross-linkers include for example SPDP and Sulfo-LC-SPDP (Pierce). The extent of derivatization with cross-linker can be influenced by varying conditions such as the concentration of each of the reaction partners, the excess of one reagent over the other, the pH, the temperature and the ionic strength. The degree of coupling, *i.e.* the amount of detectable moiety per AChR polypeptide, respectively, can be adjusted by varying the experimental conditions described above to match the requirements of the method of the invention. In a certain embodiment of the invention, the AChR polypeptide may be coupled, fused, or otherwise attached to a surface or substrate or particle.

[0063] Detectable moieties include fluorescent groups that are capable of absorbing radiation at one wavelength and emitting radiation at a longer wavelength, such as, for example, Alexa (*e.g.*, Alexa-532, Alexa-488, Alexa-647, *etc.*), Hydroxycoumarin, Aminocoumarin, Methoxycoumarin, Coumarin, Cascade Blue, Lucifer Yellow, P-Phycoerythrin, R-Phycoerythrin, (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613,

Fluorescein, BODIPY-FL, BODIPY TR, BODIPY TMR, Cy3, TRITC, X-Rhodamine, Lissamine Rhodamine B, PerCP, Texas Red, Cy5, Cy7, Allophycocyanin (APC), TruRed, APC-Cy7 conjugates, Oregon Green, Tetramethylrhodamine, Dansyl, Dansyl aziridine, Indo-1, Fura-2, FM 1-43, DilC18(3), Carboxy-SNARF-1, NBD, Indo-1, Fluo-3, DCFH, DHR, SNARF, Monochlorobimane, Calcein, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amine (NBD), ananilidonaphthalene, deproxyl, phthalamide, amino pH phthalamide, dimethylamino-naphthalenesulfonamide, probes comparable to Prodan, Lordan or Acrylodan and derivatives thereof. Coumarin fluorescent dyes include, for example, amino methylcoumarin, 7-diethylamino-3-(4'-(1-maleimidyl)phenyl)-4-methylcoumarin (CPM) and N-(2-(1-maleimidyl)ethyl)-7-diethylaminocoumarin-3-carboxamide (MDCC). Preferred fluorescent probes are sensitive to the polarity of the local environment and are available to those of skill in the art.

C. Detecting AChR Conjugate Binding

[0064] In addition to the above, the present invention also provides a kit for the evaluation, assessment, prognosis, and/or diagnosis of MG. The AChR polypeptide in the diagnosis kit may be prepared using the method as described above. In certain aspects, a labeled AChR will be provided. Additionally, in order to facilitate the identification, detection and determination of B cells according to the present invention the AChR polypeptide according to the present invention may be provided in a labeled form. In other words, the AChR polypeptide according to the present invention may be linked (covalently bonded or crosslinked) to a detectable label, i.e. provided as an AChR conjugate. Particular examples of the detectable label that may be used in the present invention include, in addition to those described above, color developing enzymes (*e.g.*, peroxidase, alkaline phosphatase, etc.), radio isotopes (*e.g.*, ^{125}I , ^{32}P , ^{35}S , ^{131}I , ^{124}I , ^{18}F , Tc99m etc.), chromophores, light emitting materials or fluorescent materials (*e.g.*, FITC, RITC, etc.). In certain aspects the label is a fluorophore such as an Alexa fluorophore. Similarly, as the detectable label, it is possible to use an antibody epitope, substrate, cofactor, inhibitor or affinity ligand. Such labeling work may be performed during or after the preparation of the AChR polypeptide.

[0065] If a fluorescent material is used as the detectable material, evaluation of AChR reactive B cells may be performed by an immunofluorescence staining method. For example, after the AChR polypeptide according to the present invention, labeled with a fluorescent material, is allowed to react with a B cell, fluorescence caused by the AChR polypeptide may

be detected by a number of devices. If any fluorescence is observed, the B cell is recognized as a AChR reactive B cell. Additionally, if an enzyme is used as the detectable label, absorbance is measured by the enzymatic color developing reaction of a substrate. On the other hand, if a radioactive material is used as the detectable label, radiation quantity is measured to detect an AChR reactive B cell, and thus to diagnose MG.

II. POLYPEPTIDES AND PEPTIDES

[0066] As used herein, a “protein” or “polypeptide” refers to a molecule comprising at least ten amino acid residues. In some embodiments, a wild-type version of a protein or polypeptide are employed, however, in many embodiments of the invention, a modified protein or polypeptide is employed to evaluate the immune status of a subject. The terms described above may be used interchangeably. A “modified protein” or “modified polypeptide” refers to a protein or polypeptide whose chemical structure, particularly its amino acid sequence, is altered with respect to the wild-type protein or polypeptide. In some embodiments, a modified protein or polypeptide has at least one modified activity or function (recognizing that proteins or polypeptides may have multiple activities or functions). It is specifically contemplated that a modified protein or polypeptide may be altered with respect to one activity or function yet retain a wild-type activity or function in other respects, such as binding affinity for AChR reactive B cells.

[0067] In certain embodiments the size of a protein or polypeptide (wild-type or modified) may comprise, but is not limited to, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, amino molecules or greater, and any range derivable therein, or derivative of a corresponding amino sequence described or referenced herein. It is contemplated that polypeptides may be mutated by truncation, rendering them shorter than their corresponding wild-type form, but also they might be altered by fusing or conjugating a heterologous protein sequence with a particular function (*e.g.*, for targeting or localization, for enhanced immunogenicity, for purification purposes, *etc.*).

[0068] As used herein, an “amino molecule” refers to any amino acid, amino acid derivative, or amino acid mimic known in the art. In certain embodiments, the residues of the proteinaceous molecule are sequential, without any non-amino molecule interrupting the sequence of amino molecule residues. In other embodiments, the sequence may comprise one or more non-amino molecule moieties. In certain aspects, the sequence of residues of the proteinaceous molecule may be interrupted by one or more non-amino molecule moieties. Accordingly, the term “proteinaceous composition” encompasses amino molecule sequences comprising at least one of the 20 common amino acids in naturally synthesized proteins, or at least one modified or unusual amino acid.

[0069] Proteinaceous compositions may be made by any technique known to those of skill in the art, including (i) the expression of proteins, polypeptides, or peptides through standard molecular biological techniques, (ii) the isolation of proteinaceous compounds from natural sources, or (iii) the chemical synthesis of proteinaceous materials. The nucleotide as well as the protein, polypeptide, and peptide sequences for various AChR receptors are disclosed herein, and with a number of other AChR proteins and nucleic acids that can be found in the recognized computerized databases. One such database is the National Center for Biotechnology Information's GenBank and GenPept databases (on the World Wide Web at ncbi.nlm.nih.gov/). The coding regions for these genes may be amplified and/or expressed using the techniques disclosed herein or as would be known to those of ordinary skill in the art.

[0070] Amino acid sequence variants of AChR and other polypeptides of the invention can be substitutional, insertional, or deletion variants. A modification in a polypeptide of the invention may affect 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223,

224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, or more non-contiguous or contiguous amino acids of the polypeptide, as compared to wild-type.

[0071] Deletion variants typically lack one or more residues of the native or wild-type protein. Individual residues can be deleted or a number of contiguous amino acids can be deleted. A stop codon may be introduced (by substitution or insertion) into an encoding nucleic acid sequence to generate a truncated protein. Insertional mutants typically involve the addition of material at a non-terminal point in the polypeptide. This may include the insertion of one or more residues. Terminal additions, called fusion proteins, may also be generated.

[0072] Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and may be designed to modulate one or more properties of the polypeptide, with or without the loss of other functions or properties. Substitutions may be conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine. Alternatively, substitutions may be non-conservative such that a function or activity of the polypeptide is affected. Non-conservative changes typically involve substituting a

residue with one that is chemically dissimilar, such as a polar or charged amino acid for a nonpolar or uncharged amino acid, and vice versa.

[0073] Proteins of the invention may be recombinant, or synthesized *in vitro*. Alternatively, a non-recombinant or recombinant protein may be isolated from bacteria or other expression host known in the art.

[0074] The term “functionally equivalent codon” is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also refers to codons that encode biologically equivalent amino acids (see Table below).

Table 2 Codon Table

Amino Acids				Codons
Alanine	Ala	A		GCA GCC GCG GCU
Cysteine	Cys	C		UGC UGU
Aspartic acid	Asp	D		GAC GAU
Glutamic acid	Glu	E		GAA GAG
Phenylalanine	Phe	F		UUC UUU
Glycine	Gly	G		GGA GGC GGG GGU
Histidine	His	H		CAC CAU
Isoleucine	Ile	I		AUA AUC AUU
Lysine	Lys	K		AAA AAG
Leucine	Leu	L		UUA UUG CUA CUC CUG CUU
Methionine	Met	M		AUG
Asparagine	Asn	N		AAC AAU
Proline	Pro	P		CCA CCC CCG CCU
Glutamine	Gln	Q		CAA CAG
Arginine	Arg	R		AGA AGG CGA CGC CGG CGU
Serine	Ser	S		AGC AGU UCA UCC UCG UCU
Threonine	Thr	T		ACA ACC ACG ACU
Valine	Val	V		GUA GUC GUG GUU
Tryptophan	Trp	W		UGG
Tyrosine	Tyr	Y		UAC UAU

[0075] It also will be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids, or 5' or 3' sequences, respectively, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region.

[0076] The following is a discussion based upon changing of the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of or even an increase in the interactive binding capacity with AChR reactive B cells. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid substitutions can be made in a protein sequence, and in its underlying DNA coding sequence, and nevertheless produce a protein with like properties. It is thus contemplated by the inventors that various changes may be made in sequences encoding AChR polypeptides without appreciable loss of their biological utility or activity.

[0077] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example enzymes, substrates, cell surface receptors, DNA, antibodies, antigens, and the like. It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still produce a biologically equivalent and immunologically equivalent protein.

A. Polypeptides and Polypeptide Production

[0078] The present invention describes polypeptides, peptides, and proteins for use in various embodiments of the present invention. For example, specific polypeptides are used to evaluate AChR autoreactivity. In specific embodiments, all or part of the proteins of the invention can also be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, (1984); Tam *et al.*, (1983); Merrifield, (1986); and Barany and Merrifield (1979), each incorporated herein by reference. Alternatively, recombinant DNA technology may be employed wherein

a nucleotide sequence which encodes a peptide of the invention is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression.

[0079] One embodiment of the invention includes the use of gene transfer to cells, including microorganisms, for the production and/or presentation of proteins. The gene for the protein of interest may be transferred into appropriate host cells followed by culture of cells under the appropriate conditions. A nucleic acid encoding virtually any polypeptide may be employed. The generation of recombinant expression vectors, and the elements included therein, are discussed herein. Alternatively, the protein to be produced may be an endogenous protein normally synthesized by the cell used for protein production.

[0080] A number of selection systems may be used including, but not limited to HSV thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase, and adenine phosphoribosyltransferase genes, in tk-, hgp^{rt}- or ap^{rt}- cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection: for dhfr, which confers resistance to trimethoprim and methotrexate; gpt, which confers resistance to mycophenolic acid; neo, which confers resistance to the aminoglycoside G418; and hyg^{ro}, which confers resistance to hygromycin.

III. NUCLEIC ACIDS

[0081] In certain embodiments, the present invention concerns recombinant polynucleotides encoding the proteins, polypeptides, peptides of the invention. The nucleic acid sequences for AChR polypeptides are included, all of which are incorporated by reference, and can be used to prepare an AChR polypeptide conjugate.

[0082] As used in this application, the term "polynucleotide" refers to a nucleic acid molecule that either is recombinant or has been isolated free of total genomic nucleic acid. Included within the term "polynucleotide" are oligonucleotides (nucleic acids 100 residues or less in length), recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like. Polynucleotides include, in certain aspects, regulatory sequences, isolated substantially away from their naturally occurring genes or protein encoding sequences. Polynucleotides may be RNA, DNA, analogs thereof, or a combination thereof.

[0083] In this respect, the term “gene,” “polynucleotide,” or “nucleic acid” is used for to refer to a nucleic acid that encodes a protein, polypeptide, or peptide (including any sequences required for proper transcription, post-translational modification, or localization). As will be understood by those in the art, this term encompasses genomic sequences, expression cassettes, cDNA sequences, and smaller engineered nucleic acid segments that express, or may be adapted to express, proteins, polypeptides, domains, peptides, fusion proteins, and mutants. A nucleic acid encoding all or part of a polypeptide may contain a contiguous nucleic acid sequence encoding all or a portion of such a polypeptide of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040, 1050, 1060, 1070, 1080, 1090, 1095, 1100, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 9000, 10000, or more amino acids of a polypeptide of the invention. It also is contemplated that a particular polypeptide may be encoded by nucleic acids containing variations having slightly different nucleic acid sequences but, nonetheless, encode the same or substantially similar protein.

[0084] In particular embodiments, the invention concerns isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences that encode an AChR polypeptide. The term “recombinant” may be used in conjunction with a polypeptide or the name of a specific polypeptide, and this generally refers to a polypeptide produced from a nucleic acid molecule that has been manipulated *in vitro* or that is a replication product of such a molecule. In other embodiments, the invention concerns isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences that encode an AChR polypeptide

[0085] The nucleic acid segments used in the present invention, regardless of the length of the coding sequence itself, may be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed,

with the total length preferably being limited by the ease of preparation and use in the intended recombinant nucleic acid protocol. In some cases, a nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example to allow for purification of the polypeptide, transport, secretion, post-translational modification, or for therapeutic benefits such as targeting or efficacy. As discussed above, a tag or other heterologous polypeptide may be added to the modified polypeptide-encoding sequence, wherein "heterologous" refers to a polypeptide that is not the same as the modified polypeptide.

[0086] Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

[0087] The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patents 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC® 2.0 from INVITROGEN® and BACPACK™ BACULOVIRUS EXPRESSION SYSTEM FROM CLONTECH®.

[0088] In addition to the disclosed expression systems of the invention, other examples of expression systems include STRATAGENE®'s COMPLETE CONTROL™ Inducible Mammalian Expression System, which involves a synthetic ecdysone-inducible receptor, or its pET Expression System, an *E. coli* expression system. Another example of an inducible expression system is available from INVITROGEN®, which carries the T-REX™ (tetracycline-regulated expression) System, an inducible mammalian expression system that uses the full-length CMV promoter. INVITROGEN® also provides a yeast expression system called the *Pichia methanolica* Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic yeast *Pichia methanolica*. One of skill in the art would know how to express a vector, such as an expression construct, to produce a nucleic acid sequence or its cognate polypeptide, protein, or peptide.

IV. KITS

[0089] Another embodiment of the invention is a kit comprising a AChR conjugate. Optionally, the kit comprises reagents for detecting or assessing at least a second B cell marker.

[0090] The kit comprises at least one container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container can have a sterile access port for reconstituting and/or extracting an agent (for example the container may be a vial having a stopper pierceable by a hypodermic injection needle). The label or package insert can indicate that the composition is used for assessing or evaluating MG. Additionally, the kit may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water, phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

EXAMPLES

[0091] The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

EXAMPLE 1

CONJUGATION OF ALEXA FLUOR 488 OR 647 TO ACHR

[0092] AChR was purified from Torpedo Californica electric organs (Aqautic Research Consultants, CA) according to published methods (Wu *et al.*, 1997) – AChR polypeptides include the polypeptides described in GenBank accession numbers AAR29363, AAR29362, AAR29361, AAA96705, AAA49276, AAA49275, AAA492774, including the corresponding

human homologs, each of which is incorporated herein by reference in its entirety. Purified AChR protein was run in SDS page and fraction having 2 alpha and one of each beta, gamma, and delta subunits collected are shown in FIG. 1. Alexa Fluor-AChR conjugates were made by incubating AChR with Alexa Fluor 488 or 647 reactive dye (Invitrogen) which has a succinimidyl ester moiety that reacts efficiently with primary amines of proteins. AChR was concentrated by centrifugation with CentriconYM (10,000 molecular weight) centrifugal filters (Millipore, MA). AChR was then dialyzed in PBS using Spectra/Por dialysis tubing (12-14,000 molecular weight). AChR concentration was determined by the Bio-Rad Protein assay using BSA to generate a standard curve for known protein concentration. AChR was then diluted to 2 mg/ml using PBS. Fifty microliters of 1M sodium bicarbonate (pH 8.3) was added to 500 µl of AChR. Next, AChR was added to vial of Alexa fluor reactive dye provided in the Alexa Fluor Protein Labeling Kit. (Invitrogen) and incubated for 1 hr at room temperature (RT) with constant stirring. Labeled AChR was purified according to manufacturers instructions. Concentration of labeled protein was determined as described previously.

EXAMPLE 2

TESTING THE FREQUENCY OF ACHR SPECIFIC B CELLS IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS

[0093] To identify AChR-specific B cells, C57BL6 mice (Jackson Lab) were immunized with AChR to induce experimental autoimmune myasthenia gravis (EAMG) (Wu *et al.*, 1997). Mice were sacrificed four weeks post-boost immunization and spleen cells were labeled with APC-anti-CD19, PE-anti-CD21/35, and Alexa 488-AChR. First lymphocytes were gated on single cells in suspension (FSC-A vs SSC-A, SSC-H vs SSC-W, and FSC-H vs FSC-W). Then cells were gated on B cells (APC-CD19+) and analyzed for binding of PE-CD21 (a mature B cell marker) and Alexa Flour 488 (FITC-like)-AChR. Mice immunized with AChR in complete Freund's adjuvant (CFA) had more than double the amount of mature AChR+ B cells (CD19+CD21+AChR+) than unimmunized naïve mice or CFA immunized mice. AChR in CFA immunized mice also had increased frequencies (mean 8.1 %) of AChR+ B cells in the lymph node compared to naïve mice (3.8%). Also AChR+ (APC like Alex 647-AChR) binding B cells are consistently elevated weeks post immunization and the size of a majority of these cells are large (FSC-A), indicating that these cells are activated.

[0094] Alexa-AChR binding B cells were depleted and those B cell which are not bound to Alexa-AChR were tested for AChR specific B cell proliferation. Those B cells which did not bind to Alexa-AChR failed to induce AChR specific B cell proliferation.

[0095] These results indicate that it is possible to identify the presence of AChR-specific B cells in lymphocyte populations *in vivo* in EAMG mice. Now we can directly evaluate AChR-specific B cell activation, migration, survival and function in mice with MG. The Torpedo AChR has around 90% sequence homology with human AChR and human MG patients antibodies significantly cross react with Torpedo AChR. The following protocol can be used to test the frequency of Alexa-AChR specific B cells in MG patients.

[0096] Collection of Blood and Identification of AChR binding B cell Subsets:

[0097] 1. Collect blood in K2EDTA 10ml BD Vacutainer Tubes (BD-366643, BD Biosciences). Collect 3 tubes per patient.

[0098] 2. Be sure to invert tube several times after blood has been collected.

[0099] 3. Centrifuge blood tubes for 15 min at 500g at room temperature (RT).

[00100] 4. Remove plasma .

[00101] 5. Transfer plasma free blood to 50 ml conical tube and add equal volume of RT PBS and mix well.

[00102] 6. Layer blood over equal volume of Histopaque 1077 (10771-100ml, Sigma-Aldrich).

[00103] 7. Centrifuge without break at 800g for 20min at RT.

[00104] 8. Remove lymphocyte layer and place in 15 ml conical tube. Wash with 10 ml RT PBS. Centrifuge at 300 g for 8 min at RT.

[00105] 9. Repeat wash.

[00106] 10. Resuspend cells in FACS Buffer (PBS, 2% FBS, 0.1% sodium azide) at 2×10^7 cells/ml.

[00107] 11. Block cells by incubating with human IgG (1 $\mu\text{g}/10^6$ cells) for 20 min on ice. (I-4506, Sigma Aldrich).

[00108] 12. Aliquot 100 μl of cells into 5 ml polystyrene round bottom tubes. Add 100 μl of fluorescent antibody (CD19, CD21) or fluorescent Alexa-AChR diluted in FACS Buffer (1 $\mu\text{g}/10^6$ cells).

[00109] Table 3 provides the antibody for staining to test the frequency of AChR specific B cells which are naïve/activated, memory, or plasma cells.

Table 3.

	Naïve/Activated	Memory	Plasma
APC	AChR	AChR	AChR
FITC	CD27	CD27	IgG
PE	CD43	CD138	CD27
PE-CY7	CD19	CD19	CD38

[00110] Steps include:

[00111] 1. Incubate with the above antibodies for 45 min at 4 degree C in dark.

[00112] 2. Add 2ml of RT BD Pharm Lyse Buffer (555899), mix well, and incubate for 15 min at RT in dark.

[00113] 3. Centrifuge for 5 min at 200g. Discard Buffer.

[00114] 4. Add 2ml wash buffer, vortex, and centrifuge for 5 min at 200g.

[00115] 5. Repeat wash.

[00116] 6. Resuspend 300 μl of 2% formaldehyde and store at 4°C

[00117] 7. Analyze using BD FACS-Canto.

[00118] The methods and compositions represented by these example can be used as follows: (1) For testing the frequency acetylcholine receptor specific B cells using Alexa-AChR conjugate for myasthenia gravis (MG) diagnosis, including those MG patients who are not diagnosed with the conventional sera anti-AChR antibody assay by RIA or ELISA. The Alexa-AChR conjugate could be further used as a rapid biomarker for disease activity and

testing the frequency of pathogenic B cell population during treatment of specific drugs in MG patients. (2) Flow cytometry using Alexa-AChR will provide more information about the type of cells producing anti-AChR antibodies, such as antibody class, frequency of these specific B cells, and type of B cells. Anti-AChR antibody secreting B cells ($CD38^{hi}CD20^{-}CD27^{hi}CD21^{lo}$), naive B cells ($CD19^{+}CD27^{-}CD21^{hi}CD38^{lo}$), and memory B cells ($CD19^{+}CD38^{+}CD138^{+}CD27^{+}$) and possibly plasma cells can be detected. (3) Conjugation of human AChR or human AChR subunits (alpha, beta, epsilon, delta) or its extra cellular domain with Alexa to test the frequency of human AChR or its subunit specific B cells in MG and correlating with disease activity. (4) Use of Alexa-AChR or subunits of various species to test the frequency of AChR or subunit specific B cells during various stages of development in various animal models of MG and MG.

[00119] To identify AChR-specific B cells, mice were immunized with AChR to induce experimental autoimmune myasthenia gravis (EAMG) according to published methods (Wu *et al.*, 1997). Mice were sacrificed four weeks post boost immunization with AChR in complete Freund's adjuvant. For control CFA immunized C57BL6 mice were used. Spleen cells, lymph node cells and blood mononuclear cells were labeled with APC-CD19, PE-CD21/35, and Alexa-488 AChR. First lymphocytes were gated on single cell suspension (FSC-A vs SSC-A, SSC-H vs SSC-W, and FSC-H vs FSC-W). Then cells were gated on B cells (APC-CD19⁺) and analyzed for binding of PE-CD21 (a mature B cell marker) and Alexa-488 (FITC-like) AChR. Splenocytes of mice immunized with AChR in CFA had more than double the amount of mature AChR⁺ B cells (CD19⁺CD21⁺AChR⁺) than unimmunized naïve mice and CFA immunized mice (FIG. 2). AChR in CFA immunized mice also had increased frequencies of AChR⁺ B cells in the lymph node compared to naïve mice. FIG. 3 shows AChR⁺ (APC) binding B cells (FITC-CD19⁺) frequencies in pooled lymph nodes in three separate mice with EAMG. AChR⁺ (APC like Alex 647-AChR) binding B cells are consistently elevated weeks post immunization and the size of a majority of these cells are large (FSC-A) indicating that these cells are activated (FIG. 3). In an independent experiment, Table 3 summarizes the mean percent CD19⁺ B cells which are AChR⁺ with SEM and N.

Table. 3 Percent of B cells that were AChR⁺ in lymph node and spleen by flow cytometry

	Lymph Node			Spleen		
	Mean	SEM	N	Mean	SEM	N

Naïve (pooled)	5.6	0	1	6.4	0	1
CFA+AChR	10.38	.61	7	11.36	1.5	7

[00120] To determine if B cells that bind AChR are specific for autoreactive immune responses in EAMG, B220+AChR- B cells were isolated from spleens of mice immunized with AChR in CFA. Next the inventors stimulated sorted B220+AChR- (AChR+B cell depleted), total B220+ B cells from AChR in CFA immunized mice, and naïve mice *in vitro* with 1 µg/ml AChR (FIG. 4). AChR+B cell depleted cells had significantly reduced AChR-specific proliferation responses compared to total B220+ cells from EAMG mice. These results indicate that AChR binding B cells are specific for AChR.

[00121] There are many challenges identifying rare AChR-specific B cells. These results demonstrate that it is possible to identify the presence of AChR-specific B cells in lymphocyte populations. The frequency in total lymphocytes in EAMG animals is about 200 AChR+/ 100,000. Even for *in vitro* stimulation of purified AChR+B cells a minimum of 160 million B cells per animal would need to be sorted. However, two rounds of sorting would be required to achieve greater than 95% purity of AChR+ B cells. These results indicate that it is possible to characterize AChR-specific B cells *in vivo*.

EXAMPLE 3

THE FREQUENCY OF ACETYLCHOLINE RECEPTOR-SPECIFIC B CELLS CORRELATES WITH EXPERIMENTAL MYASTHENIA GRAVIS SEVERITY

[00122] *Detection by flow cytometry of AChR-binding B cells among PBMCs of mice with EAM.G*. Given the pathological significance of complement activation in MG, the inventors conducted a comparative flow cytometry study of AChR-binding B cells which express IgM or IgG2 in mice (Christadoss, 1988). To activate AChR-specific B lymphocytes, mice were immunized multiple times with AChR in CFA. The protocol was optimized by using whole blood drawn from mice with EAMG approximately 2 weeks post the third immunization with AChR emulsified in CFA; these results were then compared to those in naïve or LPS-immunized controls. Alexa fluor 647-AChR was used as a probe for potentially autoreactive AChR-specific B cells, while staining with Alexa fluor 647-OVA was used as a negative control. Shown in FIG. 5 is the typical staining patterns observed from blood stained with

Alexa fluor -AChR, anti-B220, anti-IgM, and anti-IgG2. Alexa fluor-AChR preferentially bound to B220-expressing cells, which indicated to us that B cells are the main subset of peripheral lymphocytes capable of binding AChR (FIG. 5A). Furthermore, B220+ AChR-binding lymphocytes are most prominent in mice with EAMG. There is no significant increase in B220+ OVA-binding lymphocytes in mice with EAMG. These data suggest that the expansion of B220+ lymphocytes in mice with EAMG is specific to AChR-binding cells. To characterize these cells further, lymphocytes from the upper quadrants (B220+) were gated on and evaluated for expression of IgM or IgG2 and AChR-binding (FIG. 1B and 1C). Although all mice had B220+IgM+ AChR-binding cells, these cells appeared at the highest frequencies in mice with EAMG (FIG. 5B). Conversely, only mice with EAMG had elevated frequencies of B220+IgG2+ AChR-binding cells (FIG. 5C). Background staining of blood lymphocytes with Alexa-OVA provided results showing the AChR-binding B cells are responsible for the increase in B cell frequencies. To confirm the specificity of this assay, inhibition of Alexa fluor 647-AChR binding to B cells was shown by incubating the cells with a 10-fold excess of unlabeled AChR prior to fluorescent labeling (FIG. 6). Alexa fluor-AChR staining of total B220+ cells, and IgM+ and IgG2+ B cells was significantly reduced by inhibition with unlabeled AChR.

[00123] To determine the significance of the differences observed for AChR-binding B cell frequencies between mice with EAMG and controls, AChR-binding B cell frequency were evaluated at different time points following immunization with AChR in CFA. (FIG. 7). Using the analysis scheme described in FIG. 5, no significant differences in AChR-binding B cell frequencies were found at a week following the primary AChR immunization. After the second AChR immunization, the frequencies of AChR-binding peripheral blood B cells began to rise. Both B220+IgG2+ and B220+IgM+ AChR-binding B cell frequencies were significantly elevated compared to healthy and LPS immunized mice. After the third immunization, all subsets (B220+, B220+ IgM+, B220+IgG2+) of AChR-binding B cells analyzed were significantly elevated compared to findings with subsets in healthy naïve or LPS immunized mice (FIG. 7).

[00124] ***The appearance and frequency of peripheral blood AChR-specific B cells correlates with the severity of EAMG.*** Although the presence of serum antibodies to AChR indicates a possible diagnosis of MG, anti-AChR Ig concentrations are not reliable markers for disease severity (Christadoss *et al.*, 1985; Krolick *et al.*, 1994; Drachman *et al.*, 1982).

Clinical parameters of EAMG severity were used to determine whether the frequencies of peripheral blood AChR-specific B cells correlate with disease severity. The clinical grade of EAMG is a combination of several observed parameters of EAMG, such as posture, mobility, and muscle strength. Healthy unimmunized mice were assigned a clinical score of 0. A score of 1 is associated with no signs of EAMG prior to exercise or mild disease, a 2 indicates overall moderate symptoms of limb weakness, a score of 3 is associated with significant signs of muscle weakness without exercise and severe disease. After mice were immunized three times (day 75) with AChR in CFA, the frequencies of peripheral blood AChR-specific IgM⁺ and IgG2b⁺ B cells were compared with the clinical grade of disease (FIG. 8). Earlier time points (days 7, 28, 42) were not evaluated due to the lack of animals with severe disease. IgM⁺ AChR-specific B cells in blood had a significant correlation with the clinical grade of EAMG ($r = 0.6638$, $p < .0001$, $n = 5-7$ per grade) (FIG. 8A). IgG2b⁺ AChR-specific B cells in blood also had a strong correlation with clinical grade ($r = 0.767$, $p < .0001$, $n = 5-7$ per grade) (FIG. 8C).

[00125] Grip strength ratios are a more objective measurement of loss of muscle strength, described in detail in methods. A grip strength ratio >1 indicates an increase in strength over time, while a grip strength ratio ≤ 1 indicates a loss of grip strength overtime. Mice which developed severe EAMG would have grip strength ratios ≤ 1 . IgM⁺ AChR binding B cells in blood had a no significant correlation ($r = -.1688$, $p = .3978$, $n = 26$) with grip strength ratio (FIG. 8B). However, IgG2b⁺ AChR-binding B cells in blood had a negative correlation ($r = -.459$, $p < .016$, $n = 26$) with the grip strength ratio (FIG. 8D). Taken together, these results indicate that increased frequencies of peripheral blood AChR-specific B cells correspond to loss of limb muscle strength (grip strength ratio <1) and to higher clinical grades of disease. Furthermore, AChR-specific IgG2 expressing B cells is a good biomarker of disease severity.

[00126] ***Plasma secreted anti-AChR Igs do not correlate with the AChR-specific B cell frequencies in mice with EAMG.*** It has been previously demonstrated that sera or plasma anti-AChR Igs titers alone is not a reliable predictor of disease severity (Christadoss *et al.*, 1985; Kroick *et al.*, 1994; Lefvert *et al.*, 1978). However, this new assay demonstrated that the frequencies of AChR-specific B cells is useful biomarker for disease severity. The association between AChR-specific B-cell frequencies and plasma anti-AChR concentrations was also evaluated (FIG. 9). Mice were immunized with CFA and AChR and bled at days 7, 28, 42, and 56. Plasma was separated from cells by centrifugation and analyzed for secreted

anti-AChR Igs. Blood was then stained for AChR-binding B cells. Overall, the concentrations of anti-AChR Igs and frequencies of AChR-specific B cells tended to increase throughout the induction phase of EAMG (FIG. 9A and 9C). However, at a time when animals have no disease symptoms (day 28), plasma anti-AChR IgG2 titers are significantly elevated. After boost immunization (day 42), mice began to show signs of disease, while plasma anti-AChR IgG2 titers started to decrease, the AChR-specific, IgG2-expressing B cells first began to appear in the peripheral blood. No significant correlation was found between individual mouse plasma anti-AChR level and specific peripheral B cell populations (FIG. 9B and 9D).

[00127] MG patients have higher frequency of AChR binding B cells. Peripheral blood from MG patients positive for anti-AChR or anti-MUSK antibody or healthy control were tested for their CD19 + B cell binding to AChR by flow cytometry. Anti-AChR antibody positive MG patients, but not anti-MUSK + patients or healthy controls had higher frequency of B cells binding to AChR (Fig 10).

Materials and Methods

[00128] ***Mice and induction of EAMG.*** C57BL/6 mice were purchased from the Jackson Laboratories (Bar Harbor, Maine, USA). AChR extracted from *Torpedo californica* or from murine muscle tissue was purified on a neurotoxin affinity column, as previously described (Wu *et al.*, 2001). EAMG was induced by emulsifying 100 µl CFA with 100 µl AChR (20 µg) in PBS. A separate group of mice were immunized with 100 µl of LPS (5 mg) emulsified in incomplete Freund's adjuvant for comparison. Both groups were anesthetized, and then immunized (200 µl/animal) with multiple s.c. injections in shoulders and foot pads. Mice were immunized 3 times, 28 days apart. All animals were housed in a barrier facility at the University of Texas Medical Branch and maintained according to the Institutional Animal Care and Use Committee guidelines.

[00129] ***Clinical Evaluation of EAMG.*** Evaluation of disease severity and muscle weakness was performed immediately prior to blood draw and at 2 weeks after each immunization and measured as follows: **Grade 0**, normal mobility, posture and grip strength; **Grade 1**, hunchback posture, restricted mobility and decreased muscle grip strength after paw grip exercises; **Grade 2**, without exercise, observed hunchback posture, restricted mobility and decreased muscle grip strength; **Grade 3**, dehydrated and moribund with grade

2 weakness, death, or euthanasia due to paralysis. Mice were exercised by 30 paw grips on the cage top grid. Following exercise, and grip strength was measured by a dynamometer (Chatillon Digital Force Gauge, DFIS 2, Columbus Instruments, Columbus, OH). The grip strength ratio for each mouse at each time point was determined by dividing the average grip strength post immunization by the average grip strength prior to immunization. A grip strength ratio >1 indicates an increase in strength over time, while a grip strength ratio ≤ 1 indicates a loss of grip strength overtime.

[00130] **Conjugation of Alexa Fluor 647 to AChR.** AChR was purified from *torpedo californica* electric organs (Aquatic Research Consultants, CA) according to published methods (Wu *et al.*, 2001). AChR was concentrated by centrifugation with CentriconYM (10,000 molecular weight) centrifugal filters (Millipore, MA). AChR was then dialyzed in PBS by using Spectra/Por dialysis tubing (12-14,000 molecular weight). AChR was labeled with Alexa Fluor 647 Protein Labeling Kit (Invitrogen) according to the manufacturer's instructions.

[00131] **Blood collection, Flow Cytometry, and ELISA** Blood was collected from the tail vein into K₂EDTA microtubes at 7 days after primary immunization and at 2 weeks following the 2nd and 3rd immunization. In keeping with previously published ELISA protocols, blood was centrifuged at 500g for 15 min, and plasma removed for analysis of secreted anti-AChR-IgG (Yang *et al.*, 2005). Blood was then treated with BD Pharm Lyse Buffer. Fcγ receptors were blocked with anti-CD16/32 Ab (Ab 93, eBioscience). Fifty μl of whole blood was stained for surface markers with Alexa fluor 647 –AChR or Alexa fluor 647-Ovalbumin (Ova) and PE-Cy7-anti B220 (RA3-6B2), then fixed and permeabilized by using a Cytoperm/Cytofix kit (BD Biosciences) according to standard protocols for flow cytometry. Cells were then stained with anti-IgG2b (R12-3) and anti-IgM (eB121-15F9) Abs or isotype controls. Cell populations were determined using a BD FACS Canto and FlowJo v 7.2 (Tree Star).

[00132] **Statistics.** Cell phenotype was analyzed using an ANOVA with a two-tail p value. Correlation of cell frequencies to clinical grade, grip strength ratio, and plasma secreted anti-AChR IgG were determined by a Spearman correlation with a two-tail p value. The linear regression model was used to fit data.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

U.S. Patent 4,554,101

U.S. Patent 4,879,236

U.S. Patent 5,871,986

A Practical Approach, Atherton & Sheppard (Eds.), IRL Press, Oxford, England, 1989.

Aharonov *et al.*, *Lancet.*, 2(7930):340-2, 1975.

Balass *et al.*, *Proc. Natl. Acad. Sci. USA*, 90(22):10638-10642, 1993.

Barany and Merrifield, In: *The Peptides*, Gross and Meienhofer (Eds.), Academic Press, NY, 1-284, 1979.

Bartfeld and Fuchs, *Proc. Natl. Acad. Sci. USA*, 75(8):4006-4010, 1978.

Beeson *et al.*, *EMBO J.*, 9(7):2101-2106, 1990.

Brinkley, *Bioconjugate Chem.*, 3(1):2-13, 1992.

Changeux *et al.*, *Science*, 225(4668):1335-1345, 1984.

Chemical Approaches to the Synthesis of Peptides and Proteins, Williams *et al.* (Eds.), CRC Press, Boca Raton Fla., 1997.

Christadoss *et al.*, *J. Neuroimmunol.*, 8:29-41, 1985.

Christadoss, *J. Immunol.*, 140:2589-2592, 1988.

Creighton, *Proteins; Structures and Molecular Principles*, W. H. Freeman and Co., NY, 1983

De Leon-Rodriguez *et al.*, *Chem. Eur. J.*, 10:1149-1155, 2004.

Drachman *et al.*, *N. Engl. J. Med.*, 307:769-775, 1982.

Drachman, *N. Engl. J. Med.*, 330(25):1797-1810, 1994.

Garman, In: *Non-Radioactive Labelling: A Practical Approach*, Academic Press, London, 1997.

Gene Expression Technology, *Method in Enzymology, Genetics and Molecular Biology*, Method in Enzymology, Guthrie & Fink (Eds.), Academic Press, San Diego, Calif., 1991.

Glazer *et al.*, In: *Chemical Modification of Proteins. Laboratory Techniques in Biochemistry and Molecular Biology*, Work and Work (Eds.), American Elsevier Pub. Co., NY, 1975.

- Haugland, In: *Molecular Probes Handbook of Fluorescent Probes and Research Chemicals*, Molecular Probes, Inc., 2003.
- Hitzeman *et al.*, *J. Bio. Chem.*, 255:12073-12080, 1990.
- Karlin, *J. Theor. Biol.*, 87(1):33-54, 1980.
- Krolick *et al.*, *Adv. Neuroimmunol.*, 4:475-493, 1994.
- Kyte and Doolittle, *J. Mol. Biol.*, 157(1):105-132, 1982.
- Lefvert *et al.*, *J. Neurol. Neurosurg. Psychiatry*, 41:394-403, 1978.
- Lewis *et al.*, *Bioconjugate Chem.*, 12:320-324, 2001.
- Li *et al.*, *Bioconjugate Chem.*, 13:110-115, 2002.
- Loutrari *et al.*, *Eur. J. Immunol.*, 22(9):2449-2452, 1992.
- Lundblad and Noyes, In: *Chemical Reagents for Protein Modification*, Vols. I and II, CRC Press, NY, 1984.
- Maniatis, *et al.*, *Molecular Cloning*, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1982.
- Means and Feeney, *Bioconjugate Chem.*, 1(1):2-12, 1990.
- Merrifield, *Science*, 232(4748):341-347, 1986.
- Mier *et al.*, *Bioconjugate Chem.*, 16:240-237, 2005.
- Noda *et al.*, *Nature*, 305(5937):818-823, 1983.
- Patrick and Lindstrom, *Science*, 180:871-872, 1973.
- Pfleiderer, In: *Chemical Modification of Proteins*, Modern Methods in Protein Chemistry, Tschesche (Ed.), Walter DeGryter, Berlin and NY, 1985.
- Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, NY, 2nd Ed., 1998
- Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, NY, 3rd Ed., 2000.
- Schoepfer *et al.*, *FEBS Lett.*, 226(2):235-240, 1988.
- Shenoy *et al.*, *Clin. Immunol. Immunopathol.*, 66(3):230-238, 1993.
- Souroujon *et al.*, *Ann. NY Acad. Sci.*, 681:332-334, 1993.
- Souroujon *et al.*, *Immunol. Lett.*, 34(1):19-25, 1992.
- Stewart and Young, In: *Solid Phase Peptide Synthesis*, 2d. ed., Pierce Chemical Co., 1984.
- Structures and Molecular Principles, W. H. Freeman and Co., NY, 1983.
- Tam *et al.*, *J. Am. Chem. Soc.*, 105:6442, 1983.
- Tzartos and Lindstrom, *Proc. Natl. Acad. Sci. USA*, 77(2):755-759, 1980.
- Tzartos *et al.*, *Neuroimmunol.*, 15(2):185-194, 1987.

Wong, *Chemistry of Protein Conjugation and Cross-Linking*, CRC Press, Boca Raton, Fla., 1991.

Wu *et al.*, *Curr. Protoc. Immunol.*, 15:Unit 15-18, 2001.

Wu, *et al.*, In: *Experimental Autoimmune Myasthenia Gravis in the Mouse. Current Protocols in Immunology*. John Wiley & Sons, Inc, Chap. 15.8, 1997.

CLAIMS:

1. A method of evaluating a patient for or with Myasthenia Gravis comprising the step of quantitating acetylcholine receptor (AChR) conjugate binding to B cells in a sample from the patient.
2. The method of claim 1, wherein AChR conjugate binding is evaluated with respect to a reference or standard.
3. The method of claim 1, wherein the sample is a blood sample.
4. The method of claim 1, wherein the AChR conjugate comprises a fluorophore.
5. The method of claim 4, wherein the fluorophore is an Alexa fluorophore.
6. The method of claim 5, wherein the Alexa fluorophore is Alexa-488 or Alexa-647.
7. The method of claim 1, wherein determining a level of AChR binding B cells is by flow cytometry.
8. The method of claim 1, further comprising contacting the sample with B cell marker binding agent.
9. The method of claim 8, wherein the B cell marker binding agent is an antibody.
10. The method of claim 9, wherein the marker is a cell surface molecule.
11. The method of claim 9, wherein the antibody binds IgG, CD19, CD21, CD45R, CD20, CD22, CD23, or CD81.
12. The method of claim 1, further comprising administering a treatment for myasthenia gravis.
13. A device for evaluating a patient for myasthenia gravis comprising an AChR conjugate.
14. An acetylcholine receptor conjugate comprising at least 10 consecutive amino acids of an AChR polypeptide coupled to a detectable moiety.
15. A kit for detecting acetylcholine receptor reactive B cells comprising an acetylcholine receptor conjugate.
16. A method of evaluating a patient for or with an autoimmune condition comprising the steps of:
 - (i) contacting a sample comprising B cells with a protein or peptide conjugate that specifically binds a B cell associated with the autoimmune condition;
 - (ii) determining a level of conjugate binding B cells in a sample; and
 - (iii) comparing the level of conjugate reactive B-cells with a reference or standard.

17. The method of claim 16, wherein the autoimmune condition is SLE or rheumatoid arthritis.




FIG. 1




FIG. 2




FIG. 3





FIG. 4




FIG. 5






FIG. 6

Post 3rd Immunization



Post 2nd Immunization



Post 1st Immunization




FIG. 7







FIG. 8



C



B



D





FIG. 9

**FIG. 10**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 09/52121

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - G01N 33/564 (2009.01)

USPC - 436/506

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - G01N 33/564 (2009.01)

USPC - 436/506; 436/501, 436/509, 436/504, 436/804, 436/172, 436/513

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

IPC(8) - G01N 33/456 (2009.01) - see keyword below

USPC - 436/506; 436/501, 436/509, 436/504, 436/804, 436/172, 436/513 - see keyword below

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWEST(USPT,PGPB,EPAB,JPAB); Medline, Google

Search terms: acetylcholine receptor, AchR, conjugate, B cell, Myasthenia Gravis, MG, fluorophore, Alexa, -488, -647, flow cytometry, antibody, IgG, CD19, CD21, CD45R, CD20, device, polypeptide, kit, autoimmune, SLE, rheumatoid arthritis, RA, autoimmune

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2007/0269865 A1 (FUCHS et al.) 22 November 2007 (22.11.2007), Abstract, para [0007], [0019], [0021], [0022], [0023], [0031], [0051], [0069], [0074], [0107], [0114], [0120], [0123], [0136], [0143], [0154], and [0180]	1-4,12-14 ----- 5-11, 15
X --- Y	US 2006/0286093 A1 (GROSS et al.) 21 December 2006 (21.12.2006), para [0004], [0030], [0141], [0143], and [0196]	16-17 ----- 7-11
Y	US 2007/0259421 A1 (D'AMOUR et al.) 08 November 2007 (08.11.2007), para [0068], [0451], and [0702]	5-6
Y	US 5,578,496 A (ATASSI et al.) 26 November 1996 (26.11.1996), Abstract; and col 6, ln 52-54	15
A	SILVY et al. The differentiation of human memory B cells into specific antibody-secreting cells is CD40 independent. Eur J Immunol. 1996, Vol. 26(3), p.517-24. [online]. [Retrieved on 2009.10.12]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/sites/entrez>	1-17
P, A	WIKIPEDIA, B Cell, Last updated 06 October 2009, [online]. [Retrieved on 2009.10.11]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/B_cell>	1-17

☒ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

12 October 2009 (12.10.2009)

Date of mailing of the international search report

20 OCT 2009

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 09/52121

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	ALLMAN et al. Frequency of acetylcholine receptor specific B cells correlates with experimental myasthenia gravis severity. The Journal of Immunology, 2009, 182, Vol.137(5). Abstract [online]. [Retrieved on 2009.10.08]. Retrieved from the internet: <URL: http://www.jimmunol.org/cgi/content/meeting_abstract/182/1_MeetingAbstracts/137.5 >	1-17